Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Consulting agrmnt
Director departure
Appointed director

ANAVEX LIFE SCIENCES CORP. (AVXL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/30/2023 4 MISSLING CHRISTOPHER U (President and CEO) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Sold 268,000 shares @ $7.9825, valued at $2.1M
Exercised 268,000 options to buy @ $1.6, valued at $428.8k
Exercised 232,000 options to buy @ $1.6, valued at $371.2k
05/24/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/14/2023 8-K Quarterly results
04/04/2023 4 Ma Jiong (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Granted 50,000 options to buy @ $8.57, valued at $428.5k
04/04/2023 4 Thomas Steffen (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Granted 50,000 options to buy @ $8.57, valued at $428.5k
04/04/2023 4 Velden Claus Vander (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Granted 50,000 options to buy @ $8.57, valued at $428.5k
04/04/2023 4 Donhauser Peter D.O. (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Granted 50,000 options to buy @ $8.57, valued at $428.5k
04/04/2023 4 Skarpelos Athanasios (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Granted 50,000 options to buy @ $8.57, valued at $428.5k
04/04/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/04/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 5.3% stake in Anavex Life Sciences Corp.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Letter re: Prospectus Supplement"
02/07/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/07/2023 10-Q Quarterly Report for the period ended December 31, 2022
01/31/2023 SC 13G/A BlackRock Inc. reports a 7.2% stake in ANAVEX LIFE SCIENCES CORP
01/27/2023 10-K/A Annual Report for the period ended September 30, 2022 [amend]
12/02/2022 8-K Quarterly results
11/28/2022 10-K Annual Report for the period ended September 30, 2022
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/29/2022 4 Velden Claus Vander (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Granted 50,000 options to buy @ $10.09, valued at $504.5k
06/29/2022 4 Thomas Steffen (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Granted 50,000 options to buy @ $10.09, valued at $504.5k
06/29/2022 4 Donhauser Peter D.O. (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Granted 50,000 options to buy @ $10.09, valued at $504.5k
06/29/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/29/2022 4 Ma Jiong (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.
Txns: Granted 50,000 options to buy @ $10.09, valued at $504.5k
06/10/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/27/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/27/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/11/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/11/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/08/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDMENT"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy